Search
forResearch 10 of 775
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
- Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
- CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1.
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Sudden improvement of alopecia universalis and psoriatic arthritis while receiving upadacitinib: a case-based review
- Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
Learn
— no results
Try a deeper search in learn →Community
— no results
Try a deeper search in community →